Quickcool AB: Directed share issue to the European High Growth Opportunities Securitization Fund
The Board of Directors of QuickCool AB (publ) ("QuickCool"), supported by the authorization from the annual general meeting on May 7, 2019, decided and implemented a directed share issue, with exemption from the shareholders ' preferential rights. The new share issue has been addressed to the European High Growth opportunities Securitization Fund.
The purpose of the directed share issue has been to fulfil one of the terms of the financing agreement that Quickcool entered with the European High Growth Opportunities Securitization Fund. Information about the financing agreement was provided through a press release on 21 June 2018. The Board of Directors has made the assessment that the share issue is the preferred modus operandi for the company to meet the terms of the agreement.
Through the directed share issue, 1 466 664 shares will be issued which corresponds to an increase in the share capital by SEK 1 466 664. The payment of the shares has been made by offsetting the debt, which corresponds to a total amount of SEK 1 476 264.
After registering with the Swedish Companies Registration Office, QuickCool’s total share capital amounts to SEK 13 038 979 and the total number of shares to 13 038 979.
For additional information, please contact:
Fredrik Radencrantz, CEO
Phone: 046-286 38 40
E-mail: fredrik.radencrantz@quickcool.se
This information is such that QuickCool AB is required to make public in accordance with the EU’s market abuse regulation (MAR). The information was made publicly available by the Company’s contact person on 28 February, 2020.
QuickCool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the QuickCool® SYSTEM. QuickCool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. QuickCool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund.
For more Information, please refer to www.quickcool.se